A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Study acronym: VacSYn
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jan 2028 → Jun 2028
See other at-risk trials from AC Immune SA

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jan 2028 to Jun 2028 Show 5 more changesShow less
    • Eligibility criteria expanded, about 303 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description expanded, about 52 words
    • Site details revised at 2 of 12 sites
    • Publications: details revised at 1 of 1 entry
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study description revised
    • Site details revised at 12 of 12 sites
    • Study title shortened, about 1 word
    v5
  3. Site details revised at 1 of 12 sitesv4
  4. Site details revised at 2 of 12 sitesv3
  5. Study sites: 9 to 12v2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
Trial Details
NCT Number NCT06015841
Lead Sponsor AC Immune SA
Collaborators: ICON Clinical Research
Conditions
(from sponsor)		 Parkinson Disease, Parkinson Disease 6, Early-Onset
Related terms Parkinson Disease, Parkinson Disease 6, Autosomal Recessive Early-Onset
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov